Akira Kumakura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akira Kumakura has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Daisuke Hata
Department of Pediatrics, Kitano Hospital, The Tazuke Kofukai Medical Institute, Osaka, Japan
4 shared publications- Daisuke Hata
Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
3 shared publications - Atsuko Hata
Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
2 shared publications - Hiroshi Mizumoto
Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
2 shared publications - Hitoshi Nishida
Department of Pediatrics; Kitano Hospital; The Tazuke Kofukai Medical Research Institute; Osaka, Japan
2 shared publications Junko Asada
Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
2 shared publications
Latest Publications
- 18 August 2016
- Published by Elsevier in Brain and Development
- Vol. 39 (1) , 72-74
Two mild cases of Dravet syndrome with truncating mutation of SCN1A
- 18 August 2016
- Published by Elsevier in Brain and Development
- Vol. 39 (1) , 72-74
Two mild cases of Dravet syndrome with truncating mutation of SCN1A
- 1 September 2014
- Published by Elsevier in Brain and Development
- Vol. 36 (8) , 725-729
A haploinsufficiency of FOXG1 identified in a boy with congenital variant of Rett syndrome
- 1 September 2014
- Published by Elsevier in Brain and Development
- Vol. 36 (8) , 725-729
A haploinsufficiency of FOXG1 identified in a boy with congenital variant of Rett syndrome
- 1 May 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (5) , 587-591
Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan
Immunization of health care personnel (HCP) is critically important to reduce healthcare-associated influenza infections substantially. During 2009–2010, 74% of all HCP at Kitano Hospital, Osaka, Japan, including 94% of pediatricians, received the monovalent unadjuvanted influenza A (H1N1) pdm09 vaccine. We evaluated the vaccine’s immunogenicity. Sixteen pediatricians received 15 μg hemagglutinin antigen subcutaneously. Antibody titer assays were conducted using hemagglutination-inhibition antibody assay on days 0 and 21 and at 5 mo after vaccination. Seroprotection rates, seroconversion rates, and geometric mean titer folds at 21 d were, respectively, 43.8%, 43.8% and 5.4 in all subjects, 70.0%, 70.0% and 8.0 in subjects aged 27–34 y, and 0.0%, 0.0% and 8.0 in subjects aged ≥ 35 y. None of the latter group met the European Medicines Agency criteria. We hope to adopt intradermal routes and further the development of the influenza vaccine using new technology to improve immunogenicity in Japan.
- 1 May 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (5) , 587-591
Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan
Immunization of health care personnel (HCP) is critically important to reduce healthcare-associated influenza infections substantially. During 2009–2010, 74% of all HCP at Kitano Hospital, Osaka, Japan, including 94% of pediatricians, received the monovalent unadjuvanted influenza A (H1N1) pdm09 vaccine. We evaluated the vaccine’s immunogenicity. Sixteen pediatricians received 15 μg hemagglutinin antigen subcutaneously. Antibody titer assays were conducted using hemagglutination-inhibition antibody assay on days 0 and 21 and at 5 mo after vaccination. Seroprotection rates, seroconversion rates, and geometric mean titer folds at 21 d were, respectively, 43.8%, 43.8% and 5.4 in all subjects, 70.0%, 70.0% and 8.0 in subjects aged 27–34 y, and 0.0%, 0.0% and 8.0 in subjects aged ≥ 35 y. None of the latter group met the European Medicines Agency criteria. We hope to adopt intradermal routes and further the development of the influenza vaccine using new technology to improve immunogenicity in Japan.
- 1 November 2011
- Published by Elsevier in Pediatric Neurology
- Vol. 45 (5) , 344-346
Pandemic Influenza A-Associated Acute Necrotizing Encephalopathy Without Neurologic Sequelae
- 1 November 2011
- Published by Elsevier in Pediatric Neurology
- Vol. 45 (5) , 344-346
Pandemic Influenza A-Associated Acute Necrotizing Encephalopathy Without Neurologic Sequelae
- 27 January 2011
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 28 (3) , 209-216
Depressed Levels of Interferon-Gamma and HLA-DR+CD3+ T Cells in Infants with Transient Hyperferritinemia
Familial hemophagocytic lymphohistiocytosis (FHL), which typically has its onset during infancy, is uniformly fatal if not treated. It therefore requires prompt therapeutic intervention. Although hyperferritinemia has been emphasized as a useful marker for FHL, some nonfatal cases in infants with spontaneous remission also manifest with hyperferritinemia. However, distinguishing them is difficult because initial clinical features of these infants are similar. The authors encountered 14 infants with hyperferritinemia (serum ferritin >674 ng/mL), which normalized within 3 weeks following a benign clinical course. The authors compared the levels of HLA-DR+CD3+ T-cell subsets and interferon-gamma (IFN-γ) in the peripheral blood between these infants and FHL cases: one of the authors' own patients and others from the literature. Serum IFN-γ was not detected in infants with hyperferritinemia. Moreover, levels of HLA-DR+CD3+ T cells were extremely depressed. In contrast, serum IFN-γ was elevated and HLA-DR+CD3+ T cells were not depressed in FHL. Measurement of activated T cells and serum IFN-γ might help differentiate FHL in febrile infants with transient hyperferritinemia.
- 27 January 2011
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 28 (3) , 209-216
Depressed Levels of Interferon-Gamma and HLA-DR+CD3+ T Cells in Infants with Transient Hyperferritinemia
Familial hemophagocytic lymphohistiocytosis (FHL), which typically has its onset during infancy, is uniformly fatal if not treated. It therefore requires prompt therapeutic intervention. Although hyperferritinemia has been emphasized as a useful marker for FHL, some nonfatal cases in infants with spontaneous remission also manifest with hyperferritinemia. However, distinguishing them is difficult because initial clinical features of these infants are similar. The authors encountered 14 infants with hyperferritinemia (serum ferritin >674 ng/mL), which normalized within 3 weeks following a benign clinical course. The authors compared the levels of HLA-DR+CD3+ T-cell subsets and interferon-gamma (IFN-γ) in the peripheral blood between these infants and FHL cases: one of the authors' own patients and others from the literature. Serum IFN-γ was not detected in infants with hyperferritinemia. Moreover, levels of HLA-DR+CD3+ T cells were extremely depressed. In contrast, serum IFN-γ was elevated and HLA-DR+CD3+ T cells were not depressed in FHL. Measurement of activated T cells and serum IFN-γ might help differentiate FHL in febrile infants with transient hyperferritinemia.
- 1 October 2009
- Published by Elsevier in Pediatric Neurology
- Vol. 41 (4) , 309-311
Diffusion-Weighted Imaging in Preclinical Leigh Syndrome
- 1 October 2009
- Published by Elsevier in Pediatric Neurology
- Vol. 41 (4) , 309-311
Diffusion-Weighted Imaging in Preclinical Leigh Syndrome
- 1 February 2009
- Published by Elsevier in Brain and Development
- Vol. 31 (2) , 179-182
Novel de novo splice-site mutation of SCN1A in a patient with partial epilepsy with febrile seizures plus
- 1 February 2009
- Published by Elsevier in Brain and Development
- Vol. 31 (2) , 179-182
Novel de novo splice-site mutation of SCN1A in a patient with partial epilepsy with febrile seizures plus
- 1 November 2003
- Vol. 35 (6) , 521-6
[Intractable epilepsy (apneic seizure) in an infant with 18q deletion syndrome].
We report here an infant with 18q deletion syndrome, and intractable apneic seizures. He had intrauterine growth retardation and dysmorphic features. Chromosomal analysis demonstrated mosaicism of 18q interstitial deletion (q12.3-q22.3). From the age of 3 months, apneic attacks occurred from once a week to over 10 times a day despite many oral antiepileptic agents, and were diagnosed as complex partial seizures. Ictal electroencephalogram and 18F-fluorodeoxyglucose-positron emission tomography at the age of 10 months identified the epileptic focus in the right parieto-temporal region. He also had severe psychomotor retardation. Head MRI examination revealed diffuse cerebral atrophy and severe white matter dysmyelination, which was caused by the deletion of myelin basic protein gene at the locus of 18q22.3. This locus may be responsible for the clinical manifestations of 18q deletion syndrome. Detailed description of the onset, seizure types, and prognosis of epilepsy associated with 18q deletion syndrome is rare. It was suggested that the locus of 18q21.3-q22.3 was responsible for autonomic seizures in 18q deletion syndrome.
- 1 November 2003
- Vol. 35 (6) , 521-6
[Intractable epilepsy (apneic seizure) in an infant with 18q deletion syndrome].
We report here an infant with 18q deletion syndrome, and intractable apneic seizures. He had intrauterine growth retardation and dysmorphic features. Chromosomal analysis demonstrated mosaicism of 18q interstitial deletion (q12.3-q22.3). From the age of 3 months, apneic attacks occurred from once a week to over 10 times a day despite many oral antiepileptic agents, and were diagnosed as complex partial seizures. Ictal electroencephalogram and 18F-fluorodeoxyglucose-positron emission tomography at the age of 10 months identified the epileptic focus in the right parieto-temporal region. He also had severe psychomotor retardation. Head MRI examination revealed diffuse cerebral atrophy and severe white matter dysmyelination, which was caused by the deletion of myelin basic protein gene at the locus of 18q22.3. This locus may be responsible for the clinical manifestations of 18q deletion syndrome. Detailed description of the onset, seizure types, and prognosis of epilepsy associated with 18q deletion syndrome is rare. It was suggested that the locus of 18q21.3-q22.3 was responsible for autonomic seizures in 18q deletion syndrome.